The long-term study, part of CombiGene's epilepsy project, is a decisive preclinical proof-of-concept-study, the results of which will have a great bearing on the continued development of CombiGene's candidate drug, CG01. Heading the study at Skåne...read more
On the 9th of November, ARM (Alliance for Regenerative Medicine) together with Catapult (a British organisation for cell- and gene therapy) organised an investor day in London to present interesting and innovative companies at research’s forefront. Among...read more
Find it easy
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"